SUBSCRIBE
SUBSCRIBE

Vistagen

NEWS
Business
BioSpace Movers & Shakers. Dec. 4
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
December 3, 2020
 · 
7 min read
 · 
Alex Keown
Drug Development
VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
VistaGen’s oral NMDA receptor glycine B antagonist in Phase 2 development for adjunctive treatment of major depressive disorder.
November 13, 2018
 · 
1 min read
VistaGen Therapeutics.jpg
Business
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals for As-Needed Treatment of Social Anxiety Disorder
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
September 22, 2018
 · 
9 min read
AWARDS
JOBS
IN THE PRESS
Press Releases
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
November 7, 2024
 · 
12 min read
Press Releases
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
November 5, 2024
 · 
6 min read
Press Releases
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
November 1, 2024
 · 
2 min read
Press Releases
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
October 9, 2024
 · 
5 min read
Press Releases
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 23, 2024
 · 
8 min read
Press Releases
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 9, 2024
 · 
6 min read
Biotech Bay
Vistagen to Present at the Jefferies Global Healthcare Conference
May 29, 2024
 · 
1 min read
Biotech Bay
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
May 23, 2024
 · 
6 min read
Biotech Bay
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 9, 2024
 · 
6 min read
Drug Development
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 1, 2024
 · 
7 min read
Load More